Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Insulet ( (PODD) ) has provided an announcement.
On September 16, 2025, Insulet Corporation announced the appointment of Flavia Pease as the new Chief Financial Officer, succeeding Ana Maria Chadwick. This transition is expected to ensure continued financial stability and growth, as Pease brings extensive experience from her previous roles at Charles River Laboratories and Johnson & Johnson. Additionally, Insulet anticipates exceeding its third-quarter 2025 revenue growth guidance, driven by strong new customer starts in both U.S. and international markets, which reflects positively on its market performance and future outlook.
The most recent analyst rating on (PODD) stock is a Buy with a $365.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.
Spark’s Take on PODD Stock
According to Spark, TipRanks’ AI Analyst, PODD is a Outperform.
Insulet Corporation’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust revenue growth and improved leverage position, along with raised guidance, contribute significantly to its attractiveness. However, the high valuation and potential short-term overbought condition slightly temper the overall score.
To see Spark’s full report on PODD stock, click here.
More about Insulet
Insulet Corporation, headquartered in Massachusetts, is a leading medical device company specializing in diabetes management through its Omnipod product platform. The company offers a tubeless insulin pump system that provides a unique alternative to traditional insulin delivery methods, integrating with continuous glucose monitors for automated blood sugar management.
Average Trading Volume: 655,710
Technical Sentiment Signal: Buy
Current Market Cap: $23.95B
See more insights into PODD stock on TipRanks’ Stock Analysis page.